Scarica l'app Stockscreener
213.97
0.26%
-0.56
Dopo l'orario di chiusura:
213.97
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$214.53
Aprire:
$215.87
Volume 24 ore:
1.76M
Relative Volume:
1.74
Capitalizzazione di mercato:
$31.43B
Reddito:
$4.93B
Utile/perdita netta:
$1.25B
Rapporto P/E:
25.26
EPS:
8.47
Flusso di cassa netto:
$1.38B
1 W Prestazione:
+4.61%
1M Prestazione:
-4.55%
6M Prestazione:
-10.54%
1 anno Prestazione:
+15.60%
Intervallo 1D:
$212.05
$217.38
Intervallo di 1 settimana:
$201.90
$218.14
Portata 52W:
$172.19
$263.05
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Confronta RMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
213.97 | 31.43B | 4.93B | 1.25B | 1.38B | 8.47 |
|
ISRG
Intuitive Surgical Inc
|
488.27 | 174.93B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
202.04 | 58.01B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
91.42 | 45.22B | 9.91B | 1.02B | 665.00M | 2.05 |
|
COO
The Cooper Companies, Inc.
|
77.80 | 15.49B | 3.90B | 392.30M | 288.10M | 1.95 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo Finance
Earnings Preview: What to Expect From ResMed’s Report - TradingView
ResMed (RMD) Placed on Citi's 90-Day Downside Catalyst Watch | R - GuruFocus
Positive Outlook for Resmed Inc: Buy Rating Despite Short-Term Challenges - TipRanks
ResMed CFO Brett Sandercock sells $215,580 in stock By Investing.com - Investing.com Canada
Sonic and ResMed rejoin the Buy List - Intelligent Investor
ResMed CFO Brett Sandercock sells $215,580 in stock - Investing.com Australia
Why I'm taking a closer look at ResMed shares - The Motley Fool Australia
ResMed's Fiscal Q3 Likely to Meet Consensus Estimates; Faces Supply Chain Risks, UBS Says - MarketScreener
ResMed CEO Michael Farrell sells $1.68 million in stock By Investing.com - Investing.com India
Resmed Insider Sold Shares Worth $1,680,699, According to a Recent SEC Filing - MarketScreener
ResMed CEO Michael Farrell sells $1.68 million in stock - Investing.com
ResMed CFO Sells Shares - MarketScreener
ResMed Inc. Officer Plans to Sell Shares Under Rule 144 - TipRanks
Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength? - Yahoo Finance
Resmed launches HSAT across US - HME News
ResMed Inc Chairman Emeritus Adjusts Stock Holdings - TipRanks
ResMed director Peter Farrell sells $439,480 in stock By Investing.com - Investing.com South Africa
ResMed director Peter Farrell sells $439,480 in stock - Investing.com
Resmed debuts wearable, at-home sleep apnea test - Fierce Biotech
RMD Stock Benefits From the Launch of NightOwl Across US - TradingView
Should I buy Fisher & Paykel or ResMed shares? - MSN
ResMed’s global general counsel sells $14,263 in stock By Investing.com - Investing.com Canada
ResMed Launches Home Sleep Apnea Test Across US; Shares Fall 3% - MarketScreener
ResMed Inc Reports Changes in CDI and Securities Issuance - TipRanks
ResMed Inc’s General Counsel Reports Stock Transaction - TipRanks
ResMed launches at-home sleep apnea test - MassDevice
ResMed’s global general counsel sells $14,263 in stock - Investing.com India
ResMed (NYSE:RMD) Launches NightOwl Device to Simplify Home Sleep Apnea Testing Across US - Yahoo Finance
Investing in ResMed (NYSE:RMD) five years ago would have delivered you a 50% gain - simplywall.st
Resmed Launches NightOwl Home Sleep Apnea Test - Medical Product Outsourcing
ResMed Inc. (RMD): A Bull Case Theory - Insider Monkey
Game-Changing Sleep Apnea Test: Resmed's Tiny Device Tackles 80% Diagnosis Gap - Stock Titan
Resmed To Report Third Quarter Fiscal 2025 Earnings On April 23, 2025 - MarketScreener
ResMed Director Announces Sale of Common Shares - TipRanks
Resmed to Announce Q3 Fiscal 2025 Earnings - TipRanks
Resmed Inc. (RMD): Jim Cramer Says He Likes This Sleep Apnea Treatment Stock - Insider Monkey
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025 - Bluefield Daily Telegraph
ResMed Sets Date for Q3 Earnings: Key Financial Results Coming April 23 - Stock Titan
ResMed Inc. (NYSE:RMD) Stake Increased by NEOS Investment Management LLC - MarketBeat
Jim Cramer On ResMed Inc. (RMD) – “I’m With Mick! ResMed’s Doing Quite Well” - Insider Monkey
ResMed Inc. (NYSE:RMD) is a favorite amongst institutional investors who own 72% - simplywall.st
Solid sales from ASX healthcare leader - Morningstar.com.au
Is ResMed Stock Outperforming the Dow? - Nasdaq
ResMed initiated with an Overweight at Morgan Stanley - Yahoo Finance
Is ResMed Stock Outperforming The Dow? - Barchart
Resmed Says CPAP Therapy Reduces Risk Of Death By 37% In Sleep Apnea Patients - Nasdaq
Resmed’s Brand Evolution - Sleep Review
Aviso Financial Inc. Purchases 5,310 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
Why ResMed (RMD) is a Top Growth Stock for the Long-Term - Yahoo Finance
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
1.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):